Mirum Pharmaceuticals Inc (MIRM)

$39.44

+1.78

(+4.73%)

Market is closed - opens 7 PM, 15 Jul 2024

Insights on Mirum Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 69.55M → 69.22M (in $), with an average decrease of 0.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -33.14M → -25.27M (in $), with an average increase of 31.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 80.7% return, outperforming this stock by 37.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 222.8% return, outperforming this stock by 96.1%

Performance

  • $37.40
    $39.88
    $39.44
    downward going graph

    5.17%

    Downside

    Day's Volatility :6.22%

    Upside

    1.1%

    downward going graph
  • $23.14
    $39.44
    $39.44
    downward going graph

    41.33%

    Downside

    52 Weeks Volatility :41.33%

    Upside

    0.0%

    downward going graph

Returns

PeriodMirum Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
53.21%
6.1%
0.0%
6 Months
38.0%
4.9%
0.0%
1 Year
43.19%
13.6%
0.0%
3 Years
126.73%
14.3%
-22.5%

Highlights

Market Capitalization
1.7B
Book Value
$4.99
Earnings Per Share (EPS)
-3.74
Wall Street Target Price
59.0
Profit Margin
-70.79%
Operating Margin TTM
-38.24%
Return On Assets TTM
-13.76%
Return On Equity TTM
-84.4%
Revenue TTM
224.0M
Revenue Per Share TTM
5.19
Quarterly Revenue Growth YOY
119.10000000000001%
Gross Profit TTM
64.7M
EBITDA
-93.3M
Diluted Eps TTM
-3.74
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.62
EPS Estimate Next Year
-0.33
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.44

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Mirum Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
15
15
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 49.59%

Current $39.44
Target $59.00

Technicals Summary

Sell

Neutral

Buy

Mirum Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
39.48%
38.0%
43.19%
126.73%
185.09%
Moderna, Inc.
Moderna, Inc.
-16.86%
15.92%
-2.46%
-48.68%
764.93%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.12%
15.76%
50.37%
88.19%
269.25%
Novo Nordisk A/s
Novo Nordisk A/s
-2.42%
30.45%
80.67%
222.84%
488.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.43%
13.55%
42.21%
148.12%
179.95%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
NA
NA
NA
-1.62
-0.84
-0.14
NA
4.99
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.64
31.64
1.46
44.29
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.22
49.22
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.02
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
Buy
$1.7B
185.09%
NA
-70.79%
Moderna, Inc.
Moderna, Inc.
Buy
$47.1B
764.93%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$118.0B
269.25%
31.64
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$635.7B
488.09%
49.22
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
179.95%
31.94
39.46%

Institutional Holdings

  • Bvf Inc

    9.27%
  • Eventide Asset Management, LLC

    7.00%
  • State Street Corporation

    5.99%
  • HHG PLC

    5.87%
  • BlackRock Inc

    5.20%
  • Cadian Capital Management LP

    4.86%

Company Information

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.

Organization
Mirum Pharmaceuticals Inc
Employees
278
CEO
Mr. Christopher Peetz
Industry
Health Technology

FAQs